Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Vaxart is actively seeking more information about why it was told to stop work under a federally funded COVID-19 vaccine ...

Another Massachusetts biotech has reached the end of the road. | Another Massachusetts biotech has reached the end of the ...

Young inflammatory disease biotech Expedition Therapeutics is paying $17 million cash for licensing rights to an ...

Shortly after obtaining a green light from the FDA, SetPoint Medical announced $140 million in new funding to juice the commercialization of its neuromodulation implant for rheumatoid art | Shortly ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

The deal, which was signed in April 2024, saw Ipsen agree to hand over $75 million in a combination of upfront payment and ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Bicycle Therapeutics is reducing its headcount by around 25% to extend its cash runway into 2028. | Bicycle Therapeutics is ...